Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | LDHB | P07195 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017378 | 0.92 | MTOR (0.67) | MTORPIK3CAFYNATRADORA3 | |
| SCHEMBL2206879 | 0.85 | MTOR (0.58) | MTORPIK3CAFYNMAP3K11 | |
| SCHEMBL4274002 | 0.84 | MTOR (0.72) | MTORPIK3CAFYNMAP3K11 | |
| SCHEMBL4268540 | 0.83 | MTOR (0.67) | MTORFYNADORA3MAP3K11 | |
| SCHEMBL4266986 | 0.83 | MTOR (0.74) | MTORFYNADORA3MAP3K11 | |
| SCHEMBL4283434 | 0.82 | MTOR (0.71) | MTORFYNSMN1; SMN2 | |
| SCHEMBL4169485 | 0.81 | MTOR (0.64) | MTORPIK3CAFYNSMN1; SMN2MAP3K11 | |
| SCHEMBL4013052 | 0.79 | MAP3K11 (0.71) | MTORFYNMAP3K11 | |
| SCHEMBL4268568 | 0.78 | FYN (0.69) | MTORFYNADORA3MAP3K11 | |
| SCHEMBL13657423 | 0.78 | MTOR (0.63) | MTORFYNSMN1; SMN2MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | claimed |
| CN-101065016-A | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-31 | — | — | CN | claimed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | claimed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1796467-A4 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | EP | disclosed |
| CN-101065016-A | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-31 | — | — | CN | disclosed |
| EP-1796467-A2 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006036883-A2 | IMIDAZO{4,5-B}PYRAZINONE INHIBITORS OF PROTEIN KINASES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | MTOR 414/4885PIK3CA 265/4885FYN 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.